Edition:
United States

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

4.31USD
23 Feb 2018
Change (% chg)

$-0.04 (-0.92%)
Prev Close
$4.35
Open
$4.35
Day's High
$4.47
Day's Low
$4.28
Volume
6,374
Avg. Vol
5,951
52-wk High
$8.18
52-wk Low
$4.17

Chart for

About

Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company's product portfolio consists of dermatology and advanced tissue care products based upon its... (more)

Overall

Beta: 1.06
Market Cap(Mil.): $19.33
Shares Outstanding(Mil.): 4.40
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.98 16.31
EPS (TTM): -- -- --
ROI: -- 14.12 35.74
ROE: -- 15.72 17.71

BRIEF-Sonoma Pharma Revenue $4.8 Million For Third Quarter

* SONOMA PHARMACEUTICALS REPORTS RECORD TOTAL REVENUE OF $4.8 MILLION FOR THIRD QUARTER FY 2018 WITH YEAR OVER YEAR PRODUCT REVENUE GROWTH OF 46%

Feb 07 2018

BRIEF-Sonoma Pharma Gets Three New UAE Regulatory Approvals

* SONOMA PHARMACEUTICALS RECEIVES THREE NEW UNITED ARAB EMIRATES REGULATORY APPROVALS: ACUICYN® FOR MANAGEMENT OF BLEPHARITIS, MICROSAFE® ORAL CARE FOR MUCOSITIS AND SINUDOX® FOR CHRONIC SINUSITIS

Jan 09 2018

BRIEF-Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products

* SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

Dec 05 2017

BRIEF-Sonoma Pharmaceuticals announces FDA approval of expanded indication for Alevicyn

* Announces FDA approval of expanded indication for Alevicyn to add antimicrobial language

Nov 16 2017

BRIEF-Sonoma Pharmaceuticals files for mixed shelf of upto $75 mln - SEC filing ‍​

* Sonoma Pharmaceuticals Inc files for mixed shelf of upto $75 million - SEC filing ‍​ Source text: (http://bit.ly/2hfgJ1s) Further company coverage:

Nov 09 2017

BRIEF-Sonoma Pharmaceuticals posts Q2 loss $‍0.67/shr from continuing operations​

* Sonoma Pharmaceuticals reports robust top line growth for second quarter FY 2018 with 61 pct product revenue growth and total revenue of $4.3 million

Nov 09 2017

BRIEF-Sonoma Pharmaceuticals receives Brazilian approvals

* Sonoma Pharmaceuticals receives Brazilian approvals to market multiple hypochlorous acid-based dermatology products

Oct 31 2017

BRIEF-Sonoma Pharmaceuticals to commercialize company's new Loyon product in U.S.

* Announced U.S. commercialization of company's new Loyon product

Oct 03 2017

BRIEF-Sonoma Pharmaceuticals announces commercialization of Microcynah animal healthcare products in Japan

* Sonoma Pharmaceuticals announces commercialization of Microcynah animal healthcare products in Japan

Sep 14 2017

Earnings vs. Estimates